Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphatidylinositol 3-kinase alpha (PI3Kα) is a lipid kinase that plays a central role in cellular signaling pathways regulating cell growth, survival, proliferation, motility, metabolism, and angiogenesis. The enzyme is a heterodimer composed of a catalytic subunit (p110α), encoded by the PIK3CA gene, and a regulatory subunit (p85α). Mutations in the PIK3CA gene are among the most frequent oncogenic alterations found in human cancers. Common oncogenic mutations include H1047R, E542K, and E545K, which lead to constitutive activation of the PI3Kα pathway and drive oncogenesis. PIK3CA mutant forms are validated drug targets, and specific inhibitors targeting mutant PI3Kα isoforms have been developed.
Inhibition of mutant PI3Kα activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphatidylinositol 3-kinase alpha (mutant) (PI3Kα (mutant)).